Latest Lead News

Codeifai Limited has agreed to acquire its main competitor Trust Codes Global Limited, significantly expanding its footprint and product capabilities ahead of the 2027 global shift to 2D barcodes.

Lithium Universe Limited has acquired exclusive global rights to a pioneering microwave-based technology for recycling photovoltaic solar panels, offering a strategic pivot while awaiting lithium market recovery.

Blaze Minerals has inked a binding deal to acquire a major interest in the Loulombo Base Metals Project in the Republic of Congo, backed by a $2.52 million capital raise to fund exploration and development.

Emyria has landed a multi-year funding deal with Medibank to support its Empax PTSD program at Perth Clinic, marking a first for private insurer-backed psychotherapy in Australia. The company also announces a $4 million capital raise to fuel national expansion.

Viva Leisure has grown from 29 gyms in 2019 to over 480 locations, leveraging proprietary technology and a multi-brand strategy to lead fitness innovation across Australia and beyond.

X2M Connect Limited has secured $1.95 million through a share placement and convertible note conversion, aiming to strengthen its balance sheet and accelerate growth in AI and IoT sectors.

NEXTDC has locked in a substantial A$2.2 billion senior debt facility, lifting its total borrowing capacity to A$5.1 billion to support expanding data centre operations and recent contract wins.

Viridis Mining and Minerals is expanding its Viridion joint venture to develop a rare earth refinery in the U.S., leveraging Brazilian feedstock and proprietary technology to meet growing demand for secure, non-Chinese rare earths.

Bioxyne Limited, through its subsidiary Breathe Life Sciences, has secured a significant supply agreement to enter Germany’s burgeoning medical cannabis market, promising at least A$5.6 million in revenue for FY2026.

Makilala Mining has appointed leading consultants to refine and optimise the MCB Copper-Gold Project’s mine plan and infrastructure design, aiming to enhance operational efficiency and environmental outcomes.

Argenica Therapeutics has reported compelling preclinical results for ARG-007, demonstrating sustained neuroprotection and functional recovery in a ferret model of moderate traumatic brain injury. These findings pave the way for clinical trials targeting a major unmet medical need.

Bioxyne Limited's subsidiary Breathe Life Sciences has achieved key GMP certifications across multiple international markets, paving the way for expanded operations in Europe, the UK, Canada, and Singapore. The company signals strong growth prospects for FY2026, with formal guidance expected in August.